Pharming Group ADR PHAR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $14.04
- Day Range
- $13.00–14.27
- 52-Week Range
- $9.54–21.13
- Bid/Ask
- $7.24 / $19.90
- Shares Outstanding
- 70.63M
- Market Cap
- $978.87M
- Volume/Avg
- 13,766 / 10,700
Key Statistics
- Price/Earnings (Normalized)
- 45.62
- Price/Sales
- 2.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 409
- Website
- https://www.pharming.com
Valuation
|
Metric
|
PHAR
|
|---|---|
Price/Earnings (Normalized) | 45.62 |
Price/Book Value | 3.70 |
Price/Sales | 2.92 |
Price/Cash Flow | 26.31 |
Price/Earnings
PHAR
Financial Strength
|
Metric
|
PHAR
|
|---|---|
Quick Ratio | 2.05 |
Current Ratio | 2.63 |
Interest Coverage | 2.29 |
Quick Ratio
PHAR
Profitability
|
Metric
|
PHAR
|
|---|---|
Return on Assets (Normalized) | 4.54% |
Return on Equity (Normalized) | 8.31% |
Return on Invested Capital (Normalized) | 6.85% |
Return on Assets
PHAR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|XzPX<^^ | LOCK|N>rd% | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>ZSS&%! | LOCK|W?M?& | $70B | |||
| argenx SE ADR
ARGX
| LOCK|yk!%w^ | LOCK|#<^ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|s#^R^G& | LOCK|#G>^? | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#Zm?SLJ | LOCK|yWN | $36B | |||
| Moderna Inc
MRNA
| LOCK|x#KjT! | LOCK|bv | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|JTf<D!# | LOCK|prZH | $25B | |||
| Incyte Corp
INCY
| LOCK|@Xv#vw# | LOCK|w!< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|N&&drJ | LOCK|>Y^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|RL&L!vC | LOCK|vW | $17B |
United States